Short Interest in Avenue Therapeutics, Inc. (NASDAQ:ATXI) Grows By 6.1%

Avenue Therapeutics, Inc. (NASDAQ:ATXI) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 46,800 shares, an increase of 6.1% from the November 15th total of 44,100 shares. Approximately 2.7% of the shares of the stock are short sold. Based on an average daily volume of 43,900 shares, the short-interest ratio is presently 1.1 days.

Avenue Therapeutics Trading Down 3.3 %

Shares of ATXI traded down $0.06 during mid-day trading on Tuesday, reaching $1.74. 24,989 shares of the stock traded hands, compared to its average volume of 57,505. Avenue Therapeutics has a 1 year low of $1.60 and a 1 year high of $26.47. The company has a market cap of $3.57 million, a price-to-earnings ratio of 0.09 and a beta of -0.20. The firm has a fifty day moving average price of $2.05 and a 200 day moving average price of $2.66.

Hedge Funds Weigh In On Avenue Therapeutics

An institutional investor recently bought a new position in Avenue Therapeutics stock. Moss Adams Wealth Advisors LLC acquired a new position in Avenue Therapeutics, Inc. (NASDAQ:ATXI) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,000 shares of the company’s stock, valued at approximately $27,000. Moss Adams Wealth Advisors LLC owned about 1.17% of Avenue Therapeutics at the end of the most recent quarter. 17.34% of the stock is owned by institutional investors.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.